CHINARES PHARMA(03320)

4.570-0.040-0.87%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Earnings Miss: China Resources Pharmaceutical Group Limited Missed EPS By 12% And Analysts Are Revising Their Forecasts
  Simply Wall St. · 08-27
  Earnings Miss: China Resources Pharmaceutical Group Limited Missed EPS By 12% And Analysts Are Revising Their Forecasts
- BofA Securities Trims China Resources Pharma Price Target to HK$5.7, Keeps Buy Rating
  Stock News · 08-26
  BofA Securities Trims China Resources Pharma Price Target to HK$5.7, Keeps Buy Rating
- China Resources Pharmaceutical Group (SEHK:3320) Stock Trades Cheap As Margin Recovery Seeks Credibility
  Simply Wall St. · 08-25
  China Resources Pharmaceutical Group (SEHK:3320) Stock Trades Cheap As Margin Recovery Seeks Credibility
- CHINARES PHARMA declares RMB 0.087 interim dividend for H1 2026; payment set for 30 October 2026
  Bulletin Express · 08-24
  CHINARES PHARMA declares RMB 0.087 interim dividend for H1 2026; payment set for 30 October 2026
- CHINARES PHARMA Posts Stable 1H26 Results; Revenue Rises to RMB 134.46 Billion, Interim Dividend Up 21%
  Bulletin Express · 08-24
  CHINARES PHARMA Posts Stable 1H26 Results; Revenue Rises to RMB 134.46 Billion, Interim Dividend Up 21%
- China Resources Pharma Reports 5.3% Rise in Interim Net Profit to HK$2.187 Billion
  Stock News · 08-24
  China Resources Pharma Reports 5.3% Rise in Interim Net Profit to HK$2.187 Billion
- China Resources Pharmaceutical Sets October 30 Payout for Interim Dividend
  Stock News · 08-24
  China Resources Pharmaceutical Sets October 30 Payout for Interim Dividend
- China Resources Pharmaceutical Group Declares Interim Dividend of Rmb0.087 Per Share
  Reuters · 08-24
  China Resources Pharmaceutical Group Declares Interim Dividend of Rmb0.087 Per Share
- China Resources Pharmaceutical Declared an Interim Dividend of Rmb0.087 Per Share
  THOMSON REUTERS · 08-24
  China Resources Pharmaceutical Declared an Interim Dividend of Rmb0.087 Per Share
- China Resources Pharmaceutical Group H1 Revenue RMB 134,457.6 Million
  THOMSON REUTERS · 08-24
  China Resources Pharmaceutical Group H1 Revenue RMB 134,457.6 Million
- China Resources Pharmaceutical Group Says HY Revenue RMB 1.93 Billion for CR Jiangzhong
  Reuters · 08-21
  China Resources Pharmaceutical Group Says HY Revenue RMB 1.93 Billion for CR Jiangzhong
- KPC Pharmaceuticals Posts H1 2026 Net Loss of RMB 0.36 Billion as Revenue Falls 51%
  Bulletin Express · 08-21
  KPC Pharmaceuticals Posts H1 2026 Net Loss of RMB 0.36 Billion as Revenue Falls 51%
- CR Sanjiu posts 1.37% H1 2026 revenue growth; net profit slips 7.96%
  Bulletin Express · 08-21
  CR Sanjiu posts 1.37% H1 2026 revenue growth; net profit slips 7.96%
- China Resources Pharma Reports Interim Results: Subsidiary Net Profit Dips Nearly 8%
  Stock News · 08-21
  China Resources Pharma Reports Interim Results: Subsidiary Net Profit Dips Nearly 8%
- China Resources Pharmaceutical Group - Six-Month Revenue RMB 1.64 Bln, Down 50.97% for Kpc Pharmaceuticals
  THOMSON REUTERS · 08-21
  China Resources Pharmaceutical Group - Six-Month Revenue RMB 1.64 Bln, Down 50.97% for Kpc Pharmaceuticals
- CR Pharma Reports 4.91B Yuan Net Profit for Jiangzhong Unit in First Half, Down 5.92%
  Stock News · 08-21
  CR Pharma Reports 4.91B Yuan Net Profit for Jiangzhong Unit in First Half, Down 5.92%
- China Resources Pharmaceutical - Cr Jiangzhong Proposed to Distribute Cash Dividend of RMB5 for Every 10 Shares
  THOMSON REUTERS · 08-21
  China Resources Pharmaceutical - Cr Jiangzhong Proposed to Distribute Cash Dividend of RMB5 for Every 10 Shares
- China Resources Pharmaceutical Group - H1 2026 Revenue Down 2.03% to RMB 4.20 Bln for Tasly Pharmaceutical
  THOMSON REUTERS · 08-21
  China Resources Pharmaceutical Group - H1 2026 Revenue Down 2.03% to RMB 4.20 Bln for Tasly Pharmaceutical
- CR Boya Bio-Pharmaceutical, China Resources Pharmaceutical Subsidiary, Posts 77.28% Drop in H1 Net Profit Attributable to Shareholders to RMB 51.19 Million
  Reuters · 08-21
  CR Boya Bio-Pharmaceutical, China Resources Pharmaceutical Subsidiary, Posts 77.28% Drop in H1 Net Profit Attributable to Shareholders to RMB 51.19 Million
- China Resources Medical Names Yu Changjiu CFO Effective Aug. 20, 2026
  Reuters · 08-20
  China Resources Medical Names Yu Changjiu CFO Effective Aug. 20, 2026
Company Profile
Company Name
CHINARES PHARMA
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.crpharm.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
China Resources Pharmaceutical Group Ltd is an investment holding company principally engaged in the pharmaceutical business. The Company operates its business through four segments. The Pharmaceutical Business segment develops, manufactures and sells a range of pharmaceuticals and health products. The Pharmaceutical Distribution Business segment provides distribution, warehousing, logistics and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers, device manufacturer and dispensers, including hospitals, distributors and retail pharmacies. The Pharmaceutical Retail Business segment operates retail pharmacies. The Other Business Operations segment engages in property holding and other businesses.
- 08-24
  Interim Report
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
  INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026
- 04-28
  Annual Report
  2025 Annual Report
  2025 Annual Report

1D
5D
Day
Week
Month

Loading ...

High

4.640

Open

4.600

Volume%

0.63

Low

4.555

4.610

T/O Rate

0.11%

To The Moon

CHINARES PHARMA(03320)

Company Profile

Most Discussed